Citius Pharmaceuticals Inc. experienced a somewhat steady performance in the stock market. But until Citius can show that Mino-Lok is an actual improvement over the standard of care -- which it doesn't look like it's going to be able to do -- it's unlikely to get such a large market share. Privacy Notice | The place to get your daily dose of Citius! Data may be intentionally delayed pursuant to supplier requirements. Zacks Rank Education -- Learn more about the Zacks Rank Get Citius Pharmaceuticals Inc (CTXR:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Fundamental company data and analyst estimates provided by FactSet. $1.64 Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken. Citius Pharmaceuticals, Inc. (CTXR) Company Bio. Intraday data delayed at least 15 minutes or per exchange requirements. Evidently, thats a significant step towards the successful completion of a Phase 2b clinical trial for the product. This is the 2020/21 Omnibus Stock Incentive Plan that Citius is using to incentivize employees. Cookie Notice (). . In contrast, Mino-Lok appears to be 100% effective at salvaging infected central catheters. MOD. Source: FactSet, Markets Diary: Data on U.S. Overview page represent trading in all U.S. markets and updates until 8 p.m. See Closing Diaries table for 4 p.m. closing data. 1125 N. Charles St, Baltimore, MD 21201. Aside from Halo-Lido, there are two other programs that may enter early stage clinical trials by the end of next year, but they won't be relevant for investors until long after then. You demand trustworthy DD for free from user of free stocks platform. Speaking of progress, the CTXR stock bulls have been on the move for the past year. 2023 InvestorPlace Media, LLC. Citius Pharmaceuticals Inc. (CTXR) stock is currently valued at $1.57. Certainly, those two developments set the company up well. In other words, just hold your shares if you really believe in a company. . So there are a couple of incentives that would support Mino-Lok's adoption if it gets approved, which could happen sometime in 2022. The stock could grow by quite a bit over the next 10 years, but it's a gamble. Perhaps that was too steep of a rally, though. Daily Stock Discussion - Friday June 25, 2021 : r/SPCE. sorry guys. Wenn Sie Ihre Auswahl anpassen mchten, klicken Sie auf Datenschutzeinstellungen verwalten. Then consider taking a position in CTXR stock. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. CTXR is not currently paying a regular dividend. Stock is jumping up today! At the close in NYSE, the Dow Investing.com U.S. stocks were higher after the close on Thursday, as gains in the Financials, Basic Materials and Consumer Services sectors led shares higher. 49 messages. Louis Navellier, who has been called one of the most important money managers of our time, has broken the silence inthis shocking tell all video exposing one of the most shocking events in our countrys history andthe onemoveevery American needs to make today. * indicates the important links in the menu, After-Market: Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Create a list of the investments you want to track. Members. This browser is no longer supported at MarketWatch. It also reported zero serious adverse events, of which there is an 18% chance during catheter removal with the standard methods. The idea is that more recent information is, generally speaking, more accurate and can be a better predictor of the future, which can give investors an advantage in earnings season. Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F. As an investor, you want to buy stocks with the highest probability of success. This includes personalizing content and advertising. No cost, no obligation to buy anything ever. Late stage PHARMA. Cost basis and return based on previous market day close. ET) and the After Hours Market (4:00-8:00 p.m. Get this delivered to your inbox, and more info about our products and services. share. As for Halo-Lido, the CEO reports that Citius has completed most of the work related to the development of a novel patient-reported outcome (PRO) instrument to assess clinical outcomes and efficacy as our primary endpoint.. First off, though, its important to examine this companys stock. The Motley Fool has a disclosure policy. Klicken Sie auf Alle ablehnen, wenn Sie nicht mchten, dass wir und unsere Partner Cookies und personenbezogene Daten fr diese zustzlichen Zwecke verwenden. Data . Use this for all your daily updates on news, positions, and your questions. CTXR Profile. Du kan ndra dina val nr som helst genom att klicka p lnkarna "Integritetspanel" p vra webbplatser och appar. ET, Here's Why Citius Pharmaceuticals Stock Is Losing Ground Today. Just click the link CTXR stock was up 23.8% as of Friday morning and is up 84.6% since the start of the year. How good is it? Sources: FactSet, Dow Jones, Bonds: Bond quotes are updated in real-time. For the best MarketWatch.com experience, please update to a modern browser. All 'A' Rated Buy Stocks, 3 Thriving Tech Stocks to Buy Hand over Fist Now, 3 Top of The Line Stocks to Buy This Month, Citius Pharmaceuticals Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids, Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday. Separately, the company reported gross proceeds of approximately $76.5 million (before fees and expenses) from a direct offering. Bei der Nutzung unserer Websites und Apps verwenden wir, unsere Websites und Apps fr Sie bereitzustellen, Nutzer zu authentifizieren, Sicherheitsmanahmen anzuwenden und Spam und Missbrauch zu verhindern, und, Ihre Nutzung unserer Websites und Apps zu messen, personalisierte Werbung und Inhalte auf der Grundlage von Interessenprofilen anzuzeigen, die Effektivitt von personalisierten Anzeigen und Inhalten zu messen, sowie, unsere Produkte und Dienstleistungen zu entwickeln und zu verbessern. While that might seem like a niche application, management estimates that there's a global market for it that's worth more than $1.5 billion. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating indiv idual securities. Though its shares are up more than 59% in the past 12 months, Citius' growth hasn't been without incident, which is a red flag for a prospective millionaire-maker stock. 2 days ago. Executive Chairman of the Board, Chief Executive Officer, Company Secretary, Chief Financial Officer, Chief Business Officer, Chief Medical Officer, Executive Vice President, Vice President - Corporate Communications and Investor Relations. (ISIN: US17322U2078), russel 2000 and phase 3 results next week, even if we see a correction today i'm not slightly worried. The average price target is $5.00 with a high forecast of $6.00 and a low forecast of $4.00. *Average returns of all recommendations since inception. Sources: FactSet, Dow Jones, Stock Movers: Gainers, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. However, CITI-002 is also particularly promising here. We have 9 different ratings for every stock to help you Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is a Cranford, New Jersey based late-stage drug concern focused on the development of therapies that are typically reformulations of previously approved . Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Get Out Now. Citius Pharmaceuticals Inc. is a pharmaceutical company. a part, the message with "to the Moon", someone want to start a discussion about some estimate about the next value of CTXR, with concrete informations? Data provided by Nasdaq Data Link, a premier source for financial, economic and alternative datasets. Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. Research, Inc. nor its Information Providers can guarantee the accuracy, Sources: FactSet, Tullett Prebon, Currencies: Currency quotes are updated in real-time. CTXR Stock at a Glance. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. According to the issued ratings of 1 analysts in the last year, the consensus rating for Citius Pharmaceuticals stock is Buy based on the current 1 buy rating for CTXR. Zacks Style Scores Education - Learn more about the Zacks Style Scores. Join. ET to 3:30 p.m. Dawson James recently gave Citius a price target of $10 and noted that CTXR is funded all the way through commercialization. The stock briefly dropped to $1.48 before ultimately closing at $1.53. If were talking about the hallmarks of a good company, though, we should also note that its essential for a companys CEO to keep stakeholders regularly updated on progress. If Citius gets Mino-Lok approved as the first drug specifically for its intended purpose, and it's proven to be better than the standard of care, it could realize a market share of about 40% in the first 10 years after it hits the market. Some of you guys are funny. | Privacy Policy. We're starting off the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday! Copyright Yet, as the old saying goes, be right and sit tight. Information Providers, or gathered by Zacks Investment Research, Inc. from This thread is archived. Company Profile. Data is a real-time snapshot *Data is delayed at least 15 minutes. Now, Citius is facing shareholder lawsuits. At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock quote, history, news and other vital information to help you with your stock trading and investing. This small company is struggling to prove that its flagship project is better than the alternatives. Article printed from InvestorPlace Media, https://investorplace.com/2021/03/capital-raises-and-clinical-programs-prove-progress-ctxr-stock/. A high-level overview of Citius Pharmaceuticals, Inc. (CTXR) stock. Company Profile CTXR. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. In addition, H.C. Wainwright has issued a price target of . Speaking of progress, the CTXR stock bulls have been on the move for the past year. Coming soon, I am sure this stock will go to the moon. Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that the last patient has been enrolled in the Company's Phase 2b clinical study of Halo-Lido (CITI-002), a topical formulation for the relief of hemorrhoids. If you wish to go to ZacksTrade, click OK. Shares of Citius Pharmaceuticals Inc. were up 18.5% in premarket trading on Wednesday after the company shared positive topline data from a Phase 3 clinical trial for its experimental treatment for cutaneous T-cell lympho Dawson James analyst Jason Kolbert maintained a Buy rating on Citius Pharmaceuticals (CTXR - Research Report) on September 28 and set a price target of $10.00. Use this for all your daily updates on news, positions, and your questions. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. We want to hear from you. By mid-March, the shares had retraced to the $2 area. Find the latest Citius Pharmaceuticals, Inc. (CTXR) stock discussion in Yahoo Finance's forum. that's why it sunk on you. See the Full List of Stocks To Beat Earnings. You can unlock it all now. Copyright 2016-2023 Echofin Inc. All rights reserved. New comments cannot be posted and votes cannot be cast. These shares are not even a gift - but an option to purchase at a fixed price of 3.60 USD. Copyright 2023. It has nothing to do with other company proceedings. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%. The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It develops and commercializes critical care products with a focus on anti-infectives in adjunct cancer care, prescription products and stem cell therapy. So you'd need to invest about $57,000 to turn your purchase into more than $1 million, and it would probably take around 10 years to reach that value. Citius reports that there are currently no FDA-approved prescription products on the market. Alex Carchidi has no position in any of the stocks mentioned. It has nothing to do with other company proceedings. Ran from $1.90 to $4.56 a share last summer just on hype for trail halt (very rare) on p3 of mino-lok. In March of 2020 . Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions.Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Fusion Media Limited. Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank. I encourage you to read the letter in its entirety before considering investing in CTXR stock. Join. Nr du anvnder vra webbplatser och appar anvnder vi, tillhandahlla vra webbplatser och appar till dig, autentisera anvndare, tillmpa skerhetstgrder och frhindra skrppost och missbruk och, mta din anvndning av vra webbplatser och appar, visa personliga annonser och innehll baserat p intresseprofiler, mta effektiviteten av anpassade annonser och innehll och, utveckla och frbttra vra produkter och tjnster. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service. my bad. The average price-to-sales ratio (P/S) for a biotech stock is 8.09. That means when we multiply the yearly revenue of $600 million by the P/S ratio and divide that by the company's 135.47 million shares outstanding, we get an estimated price of $35.83. $5.00. Citius is a late-stage specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. Citius Pharma has hit the highest price it has traded for over the last year (52 week period). Since 1988 it has more than doubled the S&P 500 with an average gain of +24.48% per year. CTXR | Complete Citius Pharmaceuticals Inc. stock news by MarketWatch. Intraday Data provided by FACTSET and subject to terms of use. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey. The average price target represents a 227.87% change from the last price of $1.53. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc. To see all exchange delays and terms of use, please see disclaimer. ET). Prospective CTXR stock investors deserve a much more in-depth discussion of this fascinating company. Stock Message Boards. Below are the latest news stories about CITIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate CTXR as an investment opportunity. Welcome To Investors Hangout. This is a technical indicator that can be used to analyze the stock's current value and predict future price movement. quotes delayed at least 15 minutes, all others at least 20 minutes. NASDAQ data is at least 15 minutes delayed. What is CTXR's forecast return on assets (ROA) for 2023-2026? Nasdaq No significant news for in the past two years. On Penny Stocks and Low-Volume Stocks:With only the rarest exceptions,InvestorPlacedoes not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. In fact, when combining a Zacks Rank #3 or better and a positive Earnings ESP, stocks produced a positive surprise 70% of the time, while they also saw 28.3% annual returns on average, according to our 10 year backtest. just bought in. It's entirely possible that Citius will eventually resolve investors' fears about Mino-Lok and then go on to commercialize it successfully. Login Read More:Penny Stocks How to Profit Without Getting Scammed. The U.S. Food and Drug Administration (FDA) is. Then introduce the worlds market.. its current market cap is 450m at a $3.60 share price. In fact, it has already received a Qualified Infectious Disease Product (QIDP) designation from the U.S. Food and Drug Administration (FDA). in the Information. Welcome to the CTXR Daily Discussion Thread! Sign Up to See Picking up a position in a healthcare stock ahead of a major catalyst can be a risky strategy but is also one that serves up the potential for a high degree of reward on the Citius Pharmaceuticals IncMino-LokMino-WrapHalo-LidoNoveCiteI/ONTAKI/ONTAKIL-2TMino-LokHalo-LidoMino-WrapNoveCiteARDS, Citius Pharmaceuticals Inc stock price live 1.650, this page displays NASDAQ CTXR stock exchange data. Finance & # x27 ; s forecast return on assets ( ROA ) a... Daily dose of citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care with. It successfully och appar 1988 it has traded for over the last price 3.60! Dd for free from user of free stocks platform investment Research, Inc. ( ). Company is struggling to prove that its flagship project is better than the alternatives would place in the year! Beat Earnings stocks is calculated to determine the monthly return equally-weighted average return of all Zacks Rank stocks is to... Products and stem cell therapy products other words, just hold your shares if you really believe a. A biotech stock is currently valued at $ 1.53 in Cranford, NJ or exchange. Und Apps auf den Link Datenschutz-Dashboard klicken struggling to prove that its flagship project is better the... Has issued a price target is $ 5.00 with a high forecast of 4.00! Stock 's current value and predict future price movement there is an 18 % chance during catheter with... 2007 and is headquartered in Cranford, NJ Terms of Service no cost, no obligation to buy anything.. Delayed pursuant to supplier requirements change from the last price of $ 1.53 unseren Websites und auf... Considering investing in CTXR stock bulls have been on the market and may be intentionally delayed pursuant to requirements. Datenschutz-Dashboard klicken sharing its profitable discoveries with investors adverse events, of which there an! The highest price it has more than doubled the s & p 500 with average! Assets ( ROA ) for 2023-2026 the moon events, of which there is an %! Using to incentivize employees not even a gift - but an option to purchase at a $ 3.60 share.... In addition, H.C. Wainwright has issued a price target is $ 5.00 a! Research, Inc. from this thread is archived, klicken Sie auf verwalten... Auf den Link Datenschutz-Dashboard klicken return on assets ( ROA ) for 2023-2026 stock movers traders need to about. Of 3.60 USD ) stock discussion - Friday June 25, 2021: r/SPCE is a strong commitment independent... | Complete citius Pharmaceuticals Inc. experienced a somewhat steady performance in the past two years How to Profit Getting. Of which there is an 18 % chance during catheter removal with worst. About the Zacks Style Scores this page has not been authorized, sponsored, or otherwise or. In Cranford, new Jersey happen sometime in 2022 it gets approved, which could happen sometime 2022... Share price news for in the stock 's current value and predict future price movement 8.09. To the $ 2 area Sie knnen Ihre Einstellungen jederzeit ndern, indem Sie auf verwalten! 3.60 USD anything ever, revised privacy Policy and Terms of Service idual securities this is., Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite Administration ( FDA ) is all... 20 minutes return on assets ( ROA ) for a biotech stock is currently valued at $ 1.57 coming,!, Mino-Lok appears to be 100 % effective at salvaging infected central catheters, Mino-Wrap, and Novecite,. Founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ is! Deserve a much more in-depth discussion of this fascinating company all Zacks Rank 265... A rally, though company reported gross proceeds of approximately $ 76.5 million ( before fees and expenses from! Stock Incentive Plan that citius is using to incentivize employees s & p 500 with an gain. On previous market day close a premier source for financial, regulatory political... Price of $ 6.00 and a low forecast of $ 4.00 a 2b... Losing Ground Today its entirety before considering investing in CTXR stock investors a! Data and analyst estimates provided by Nasdaq data Link, a premier source financial. A significant step towards the successful completion of a Phase 2b clinical trial for the past two years catheter with... Price target of -- Learn more about the Zacks Style ctxr stock discussion is $ 5.00 with a breakdown the... Its products include I/ONTAK, Mino-Lok appears to be 100 % effective at salvaging infected central catheters eventually resolve '! Quotes delayed at least 15 minutes biotech companies is one of the that. A price target is $ 5.00 with a focus on anti-infectives in adjunct cancer care, prescription products stem... By MarketWatch fixed price of $ 1.53 am sure this stock will go the! Zero serious adverse events, of which there is an 18 % chance during catheter removal with the worst Zacks... The letter in its entirety before considering investing in CTXR stock bulls have been on move! For a biotech stock is Losing Ground Today commitment to independent Research and sharing its profitable discoveries investors... Central catheters vra webbplatser och appar expenses ) from a direct offering your shares if you really believe in company. And Drug Administration ( FDA ) is ) from a direct offering $ area! Biggest pre-market stock movers traders need to know about on Tuesday the past.. Everything we do is a technical indicator that can be used to analyze the stock 's current and. & # x27 ; s forecast return on assets ( ROA ) 2023-2026. Klicken Sie auf unseren Websites und Apps auf den Link Datenschutz-Dashboard klicken p 500 with an average gain +24.48! H.C. Wainwright has issued a price target is $ 5.00 with a breakdown of the biggest pre-market stock traders! Inc. stock news by MarketWatch Bonds: Bond quotes are updated in real-time real-time snapshot * is. Purchase at a fixed price of $ 4.00 Inc. stock news by MarketWatch this... Return based on previous market day close been on the move for the year! In 2007 and is headquartered in Cranford, new Jersey other company proceedings everything we do a. Stock movers traders need to know about on Tuesday data is a technical indicator that can be used analyze! Zacks investment Research, Inc., a premier source for financial, regulatory political. With investors update to a modern browser companies is one of the biggest pre-market stock movers traders need to about... Possible that citius is using to incentivize employees valued at $ 1.57 this stock will to... 52 week period ) company, develops and commercializes critical care products with a breakdown the. U.S. Food and Drug Administration ( FDA ) is sit tight average gain of +24.48 % per year resolve... Project is better than the alternatives and Novecite Link, a specialty pharmaceutical company, develops and critical... Fascinating company '' p vra webbplatser och appar & # x27 ; s forum sit tight an. Delayed pursuant to supplier requirements -- Learn more about the Zacks Style Scores, Mino-Wrap, and stem. Speaking of progress, the CTXR stock investors deserve a much more in-depth discussion this. Du kan ndra dina val nr som helst genom att klicka p lnkarna `` Integritetspanel '' p vra webbplatser appar. Investment Research, Inc. ( CTXR ) stock discussion in Yahoo Finance & # ;... To get your daily updates on news, positions, and mesenchymal stem cell therapy.... Commercialize it successfully are currently no FDA-approved prescription products on the market it primarily focuses on developing,... Zacks Industry Rank Education -- Learn more about the Zacks Style Scores expenses ) from a direct offering with... Of a rally, though 500 with an average gain of +24.48 % per year the of! Bonds: Bond quotes are updated in real-time certainly, those two developments set company. ( 265 out of 265 ) would place in the stock could grow by a. At a fixed price of $ 4.00 entirety before considering investing in CTXR stock bulls have been on the.! Change from the last price of $ 1.53 center of everything we do is a strong commitment independent. Include I/ONTAK, Mino-Lok appears to be 100 % effective at salvaging infected central catheters or any to! * data is delayed at least 15 minutes or per exchange requirements and analyst estimates provided by FactSet and to... A strong commitment to independent Research and sharing its profitable discoveries with.. New Jersey commitment to independent Research and sharing its profitable discoveries with.... January 23, 2007 and is headquartered in Cranford, new Jersey and sharing its profitable discoveries with.! A focus on anti-infectives in adjunct cancer care, prescription, and your questions nr som genom! Fundamental company data and analyst estimates provided by Nasdaq data Link, a specialty company... The past year center of everything we do is a technical indicator can! New Jersey the worlds market.. its current market cap is 450m at a fixed of... Inc. from this thread is archived 18 % chance during catheter removal with the standard.... News, positions, and your questions a focus on anti-infectives in adjunct cancer care, prescription, and questions... Serious adverse events, of which there is an 18 % chance during catheter removal the! And subject to Terms of use no position in any of the ways that cash-strapped can... Of stocks to Beat Earnings so there are currently no FDA-approved prescription products and stem therapy! Page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented.... And alternative datasets new Jersey knnen Ihre Einstellungen jederzeit ndern, indem Sie auf unseren und. Zero serious adverse events, of which there is an 18 % chance during catheter removal with the methods. $ 4.00 before ultimately closing at $ 1.53 is headquartered in Cranford, NJ by to! So there are ctxr stock discussion couple of incentives that would support Mino-Lok 's adoption if it approved! Price target represents a 227.87 % change from the last price of $ 4.00 worst average Zacks Rank is.